[1]
Santoni, M.; Scarpelli, M.; Cheng, L.; Lopez-Beltran, A.; Massari, F.; Matrana, M.R.; Moch, H.; Montironi, R. Immunotargeting of genitourinary tumors: An overview. Curr. Drug Targets, 2016, 17(7), 750-756.
[2]
Santoni, M.; Massari, F.; Di Nunno, V.; Conti, A.; Cimadamore, A.; Scarpelli, M.; Montironi, R.; Cheng, L.; Battelli, N.; Lopez-Beltran, A. Immunotherapy in renal cell carcinoma: Latest evidence and clinical implications. Drugs Context, 2018, 7, 212528.
[3]
Motzer, R.J.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.; Plimack, E.R.; Castellano, D.; Choueiri, T.K.; Gurney, H.; Donskov, F.; Bono, P.; Wagstaff, J.; Gauler, T.C.; Ueda, T.; Tomita, Y.; Schutz, F.A.; Kollmannsberger, C.; Larkin, J.; Ravaud, A.; Simon, J.S.; Xu, L.A.; Waxman, I.M.; Sharma, P. CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med., 2015, 373, 1803-1813.
[4]
Tannir, N.M.; Hammers, H.J.; Amin, A.; Grimm, M.O.; Rini, B.I.; Mekan, S.; McHenry, M.B.; Kollmannsberger, C.K. Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214). J. Clin. Oncol., 2018, 36, 686-686.
[5]
Gevaert, T.; Montironi, R.; Lopez-Beltran, A.; Van Leenders, G.; Allory, Y.; De Ridder, D.; Claessens, F.; Kockx, M.; Akand, M.; Joniau, S.; Netto, G.; Libbrecht, L. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. Semin. Cancer Biol., 2018, 52(Pt 2), 216-227.
[6]
Mann, S.A.; Lopez-Beltran, A.; Massari, F.; Pili, R.; Fiorentino, M.; Koch, M.O.; Kaimakliotis, H.Z.; Wang, L.; Scarpelli, M.; Ciccarese, C.; Moch, H.; Montironi, R.; Cheng, L. Targeting the programmed cell death-1 pathway in genitourinary tumors: Current progress and future perspectives. Curr. Drug Metab., 2017, 18(8), 700-711.
[7]
Kucharczyk, J.; Matrana, M.R.; Santoni, M.; Massari, F.; Scarpelli, M.; Cheng, L.; Lopez-Beltran, A.; Cascinu, S.; Montironi, R.; Holger, M. Emerging Immunotargets in metastatic renal cell carcinoma. Curr. Drug Targets, 2016, 17, 771-776.
[8]
Alsaab, H.O.; Sau, S.; Alzhrani, R.; Tatiparti, K.; Bhise, K.; Kashaw, S.K.; Iyer, A.K. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front. Pharmacol., 2017, 8, 561.
[9]
Mazza, C.; Escudier, B.; Albiges, L. Nivolumab in renal cell carcinoma: Latest evidence and clinical potential. Ther. Adv. Med. Oncol., 2017, 9, 171-181.
[10]
Hirayama, Y.; Gi, M.; Yamano, S.; Tachibana, H.; Okuno, T.; Tamada, S.; Nakatani, T.; Wanibuchi, H. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma. Cancer Sci., 2016, 107, 1736-1744.
[11]
Rizvi, N.A.; Hellmann, M.D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J.J.; Lee, W.; Yuan, J.; Wong, P.; Ho, T.S.; Miller, M.L.; Rekhtman, N.; Moreira, A.L.; Ibrahim, F.; Bruggeman, C.; Gasmi, B.; Zappasodi, R.; Maeda, Y.; Sander, C.; Garon, E.B.; Merghoub, T.; Wolchok, J.D.; Schumacher, T.N.; Chan, T.A. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 2015, 348(6230), 124-128.
[12]
Riaz, N.; Havel, J.J.; Kendall, S.M.; Makarov, V.; Walsh, L.A.; Desrichard, A.; Weinhold, N.; Chan, T.A. Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nat. Genet., 2016, 48, 1327-1329.
[13]
Schumacher, T.N.; Schreiber, R.D. Neoantigens in cancer immunotherapy. Science, 2015, 348(6230), 69-74.
[14]
Spranger, S.; Bao, R.; Gajewski, T.F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature, 2015, 523, 231-235.
[15]
Smyth, M.J.; Ngiow, S.F.; Ribas, A.; Teng, M.W. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol., 2016, 13(3), 143-158.
[16]
Koyama, S.; Akbay, E.A.; Li, Y.Y.; Herter-Sprie, G.S.; Buczkowski, K.A.; Richards, W.G.; Gandhi, L.; Redig, A.J.; Rodig, S.J.; Asahina, H.; Jones, R.E.; Kulkarni, M.M.; Kuraguchi, M.; Palakurthi, S.; Fecci, P.E.; Johnson, B.E.; Janne, P.A.; Engelman, J.A.; Gangadharan, S.P.; Costa, D.B.; Freeman, G.J.; Bueno, R.; Hodi, F.S.; Dranoff, G.; Wong, K.K.; Hammerman, P.S. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun., 2016, 7, 10501.
[17]
Chovanec, M.; Cierna, Z.; Miskovska, V.; Machalekova, K.; Svetlovska, D.; Kalavska, K.; Rejlekova, K.; Spanik, S.; Kajo, K.; Babal, P.; Mardiak, J.; Mego, M. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors. Oncotarget, 2017, 8, 21794-21805.
[18]
Adra, N.; Einhorn, L.H.; Althouse, S.K.; Ammakkanavar, N.R.; Musapatika, D.; Albany, C.; Vaughn, D.; Hanna, N.H. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: A Hoosier Cancer Research Network Study GU14-206. Ann. Oncol., 2018, 29, 209-214.
[19]
Shen, H.; Shih, J.; Hollern, D.P.; Wang, L.; Bowlby, R.; Tickoo, S.K.; Thorsson, V.; Mungall, A.J.; Newton, Y.; Hegde, A.M.; Armenia, J.; Sánchez-Vega, F.; Pluta, J.; Pyle, L.C.; Mehra, R.; Reuter, V.E.; Godoy, G.; Jones, J.; Shelley, C.S.; Feldman, D.R.; Vidal, D.O.; Lessel, D.; Kulis, T.; Cárcano, F.M.; Leraas, K.M.; Lichtenberg, T.M.; Brooks, D.; Cherniack, A.D.; Cho, J.; Heiman, D.I.; Kasaian, K.; Liu, M.; Noble, M.S.; Xi, L.; Zhang, H.; Zhou, W. ZenKlusen, J.C.; Hutter, C.M.; Felau, I.; Zhang, J.; Schultz, N.; Getz, G.; Meyerson, M.; Stuart, J.M.; Cancer Genome Atlas Research Network, Akbani, R.; Wheeler, D.A.; Laird, P.W.; Nathanson, K.L.; Cortessis, V.K.; Hoadley, K.A. Integrated molecular characterization of testicular germ cell tumors. Cell Reports, 2018, 23, 3392-3406.
[20]
Routy, B.; Le Chatelier, E.; Derosa, L.; Duong, C.P.M.; Alou, M.T.; Daillère, R.; Fluckiger, A.; Messaoudene, M.; Rauber, C.; Roberti, M.P.; Fidelle, M.; Flament, C.; Poirier-Colame, V.; Opolon, P.; Klein, C.; Iribarren, K.; Mondragón, L.; Jacquelot, N.; Qu, B.; Ferrere, G.; Clémenson, C.; Mezquita, L.; Masip, J.R.; Naltet, C.; Brosseau, S.; Kaderbhai, C.; Richard, C.; Rizvi, H.; Levenez, F.; Galleron, N.; Quinquis, B.; Pons, N.; Ryffel, B.; Minard-Colin, V.; Gonin, P.; Soria, J.C.; Deutsch, E.; Loriot, Y.; Ghiringhelli, F.; Zalcman, G.; Goldwasser, F.; Escudier, B.; Hellmann, M.D.; Eggermont, A.; Raoult, D.; Albiges, L.; Kroemer, G.; Zitvogel, L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science, 2018, 359, 91-97.
[21]
Cani, P.D. Human gut microbiome: Hopes, threats and promises. Gut, 2018, 67, 1716-1725.
[22]
Cavarretta, I.; Ferrarese, R.; Cazzaniga, W.; Saita, D.; Lucianò, R.; Ceresola, E.R.; Locatelli, I.; Visconti, L.; Lavorgna, G.; Briganti, A.; Nebuloni, M.; Doglioni, C.; Clementi, M.; Montorsi, F.; Canducci, F.; Salonia, A. The microbiome of the prostate tumor microenvironment. Eur. Urol., 2017, 72, 625-631.
[23]
Sfanos, K.S.; Sauvageot, J.; Fedor, H.L.; Dick, J.D.; De Marzo, A.M.; Isaacs, W.B. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate, 2008, 68, 306-320.
[24]
Montironi, R.; Gasparrini, S.; Mazzucchelli, R.; Massari, F.; Cheng, L.; Lopez-Beltran, A.; Montorsi, F.; Scarpelli, M. Re: Karim A. Touijer, James A. Eastham. The sentinel lymph node concept and novel approaches in detecting lymph node metastasis in prostate cancer. Eur Urol 2016;70:738-9: Sentinel lymph nodes in adipose tissue surrounding the prostate gland and seminal vesicles as observed in virtual whole-mount histologic slides. Eur Urol 2017;71:e73-5. Eur. Urol., 2017, 72(2), e37-e38.
[25]
Montironi, R.; Lopez-Beltran, A.; Cheng, L.; Scarpelli, M.; Mazzucchelli, R.; Montorsi, F. Re: Antibody-drug conjugates targeting prostate-specific membrane antigen. Eur. Urol., 2014, 66(6), 1190-1193.
[26]
Wright, G.L. Jr1.; Grob, B.M.; Haley, C.; Grossman, K.; Newhall, K.; Petrylak, D.; Troyer, J.; Konchuba, A.; Schellhammer, P.F.; Moriarty, R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 1996, 48(2), 326-334.
[27]
Cimadamore, A.; Scarpelli, M.; Cheng, L.; Lopez-Beltran, A.; Montorsi, F.; Montironi, R. Re: Isabel Rauscher, Charlotte Düwel, Bernhard Haller. Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy. Eur. Urol. 2018,73,656-61: Clinical Significance of Prostate-specific Membrane Antigen Immunohistochemistry and Role of the Uropathologists. Eur. Urol., 2018, 74(6), e141-e144.
[28]
Santoni, M.; Scarpelli, M.; Mazzucchelli, R.; Lopez-Beltran, A.; Cheng, L.; Cascinu, S.; Montironi, R. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: Morphologic and molecular backgrounds and future promises. J. Biol. Regul. Homeost. Agents, 2014, 28(4), 555-563.
[29]
Rauscher, I.; Düwel, C.; Haller, B.; Rischpler, C.; Heck, M.M.; Gschwend, J.E.; Schwaiger, M.; Maurer, T.; Eiber, M. Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen-ligand positronemission tomography/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy. Eur. Urol., 2018, 73(5), 656-661.
[30]
Cimadamore, A.; Cheng, M.; Santoni, M.; Lopez-Beltran, A.; Battelli, N.; Massari, F.; Galosi, A.B.; Scarpelli, M.; Montironi, R. New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen. Front. Oncol., 2018, 8, 653.
[31]
Hope, T.A.; Truillet, C.; Ehman, E.C.; Afshar-Oromieh, A.; Aggarwal, R.; Ryan, C.J.; Carroll, P.R.; Small, E.J.; Evans, M.J. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: First human experience. J. Nucl. Med., 2017, 58(1), 81-84.
[32]
Karachaliou, N.; Mayo-de-Las-Casas, C.; Molina-Vila, M.A.; Rosell, R. Real-time liquid biopsies become a reality in cancer treatment. Ann. Transl. Med., 2015, 3(3), 36.
[33]
Allard, W.J.; Matera, J.; Miller, M.C.; Repollet, M.; Connelly, M.C.; Rao, C.; Tibbe, A.G.; Uhr, J.W.; Terstappen, L.W. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res., 2004, 10, 6897-6904.
[34]
Massari, F.; Di Nunno, V.; Comito, F.; Cubelli, M.; Ciccarese, C.; Iacovelli, R.; Fiorentino, M.; Montironi, R.; Ardizzoni, A. Circulating tumor cells in genitourinary tumors. Ther. Adv. Urol., 2017, 10(2), 65-77.
[35]
Lorente, D.; Olmos, D.; Mateo, J.; Dolling, D.; Bianchini, D.; Seed, G.; Flohr, P.; Crespo, M.; Figueiredo, I.; Miranda, S.; Scher, H.I.; Terstappen, L.W.M.M.; De Bono, J.S. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Ann. Oncol., 2018, 29, 1554-1560.
[36]
Miyamoto, D.T.; Lee, R.J.; Stott, S.L.; Wittner, B.S.; Ulman, M.; Smas, M.E.; Lord, J.B.; Brannigan, B.W.; Trautwein, J.; Bander, N.H.; Wu, C.L.; Sequist, L.V.; Smith, M.R.; Ramaswamy, S.; Toner, M.; Maheswaran, S.; Haber, D.A. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov., 2012, 2, 995-1003.
[38]
Ciccarese, C.; Montironi, R.; Fiorentino, M.; Martignoni, G.; Brunelli, M.; Iacovelli, R.; Lopez-Beltran, A.; Cheng, L.; Scarpelli, M.; Moch, H.; Tortora, G.; Massari, F. Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment? Curr. Drug Metab., 2017, 18(8), 692-699.
[39]
Ross, R.W.; Galsky, M.D.; Scher, H.I.; Magidson, J.; Wassmann, K.; Lee, G.S.; Katz, L.; Subudhi, S.K.; Anand, A.; Fleisher, M.; Kantoff, P.W.; Oh, W.K. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: A prospective study. Lancet Oncol., 2012, 13, 1105-1113.
[40]
Ulz, P.; Belic, J.; Graf, R.; Auer, M.; Lafer, I.; Fischereder, K.; Webersinke, G.; Pummer, K.; Augustin, H.; Pichler, M.; Hoefler, G.; Bauernhofer, T.; Geigl, J.B.; Heitzer, E. Speicher, M. R. Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. Nat. Commun., 2016, 7, 12008.
[41]
Romanel, A.; Gasi Tandefelt, D.; Conteduca, V.; Jayaram, A.; Casiraghi, N.; Wetterskog, D.; Salvi, S.; Amadori, D.; Zafeiriou, Z.; Rescigno, P.; Bianchini, D.; Gurioli, G.; Casadio, V.; Carreira, S.; Goodall, J.; Wingate, A.; Ferraldeschi, R.; Tunariu, N.; Flohr, P.; De Giorgi, U.; de Bono, J.S.; Demichelis, F.; Attard, G. Plasma AR and abiraterone-resistant prostate cancer. Sci. Transl. Med., 2015, 7(312), 312re10.
[42]
Gorges, T.M.; Riethdorf, S.; Von Ahsen, O.; Nastał, Y. P.; Röck, K.; Boede, M.; Peine, S.; Kuske, A.; Schmid, E.; Kneip, C.; König, F.; Rudolph, M.; Pantel, K. Heterogeneous PSMA expression on circulating tumor cells: A potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. Oncotarget, 2016, 7(23), 34930-34941.
[43]
Maetzel, D.; Denzel, S.; Mack, B.; Canis, M.; Went, P.; Benk, M.; Kieu, C.; Papior, P.; Baeuerle, P.A.; Munz, M.; Gires, O. Nuclear signalling by tumour-associated antigen EpCAM. Nat. Cell Biol., 2009, 11(2), 162-171.
[44]
Gradilone, A.; Iacovelli, R.; Cortesi, E.; Raimondi, C.; Gianni, W.; Nicolazzo, C.; Petracca, A.; Palazzo, A.; Longo, F.; Frati, L.; Gazzaniga, P. Circulating tumor cells and “suspicious objects” evaluated through CellSearch® in metastatic renal cell carcinoma. Anticancer Res., 2011, 31(12), 4219-4221.
[45]
Montironi, R.; Santoni, M.; Scarpelli, M.; Piva, F.; Lopez-Beltran, A.; Cheng, L.; Briganti, A.; Montorsi, F. Re: Epithelial-to-mesenchymal transition in renal neoplasms. Eur. Urol., 2015, 68(4), 736-737.
[46]
Piva, F.; Giulietti, M.; Santoni, M.; Occhipinti, G.; Scarpelli, M.; Lopez-Beltran, A.; Cheng, L.; Principato, G.; Montironi, R. Epithelial to mesenchymal transition in renal cell carcinoma: Implications for cancer therapy. Mol. Diagn. Ther., 2016, 20(2), 111-117.
[47]
Hanna, S.M.; Kirk, P.; Holt, O.J.; Puklavec, M.J.; Brown, M.H.; Barclay, A.N. A novel form of the membrane protein CD147 that contains an extra Ig-like domain and interacts homophilically. BMC Biochem., 2003, 4, 17.
[48]
Liu, S.; Tian, Z.; Zhang, L.; Hou, S.; Hu, S.; Wu, J.; Jing, Y.; Sun, H.; Yu, F.; Zhao, L.; Wang, R.; Tseng, H.R.; Zhau, H.E.; Chung, L.W.; Wu, K.; Wang, H.; Wu, J.B.; Nie, Y.; Shao, C. Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients. Oncotarget, 2016, 7(37), 59877-59891.
[49]
Detection of circulating cancer cells with von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma. Clin. Cancer Res., 2000, 6(10), 3817-3822.
[50]
Li, G.; Passebosc-Faure, K.; Gentil-Perret, A.; Lambert, C.; Genin, C.; Tostain, J. Cadherin-6 gene expression in conventional renal cell carcinoma: A useful marker to detect circulating tumor cells. Anticancer Res., 2005, 25, 377-381.
[51]
Goessl, C.; Müller, M.; Straub, B.; Miller, K. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur. Urol., 2002, 41, 668-676.
[52]
Brisuda, A.; Pazourkova, E.; Soukup, V.; Horinek, A.; Hrbáček, J.; Capoun, O.; Svobodova, I.; Pospisilova, S.; Korabecna, M.; Mares, J.; Hanuš, T.; Babjuk, M. Urinary cell-free DNA quantification as non-invasive biomarker in patients with bladder cancer. Urol. Int., 2016, 96, 25-31.
[53]
Bryzgunova, O.E.; Laktionov, P.P. Extracellular nucleic acids in urine: Sources, structure, diagnostic potential. Acta Naturae, 2015, 7(3), 48-54.
[54]
Chen, L.; Cui, Z.; Liu, Y.; Bai, Y.; Lan, F. MicroRNAs as biomarkers for the diagnostics of bladder cancer: A meta-analysis. Clin. Lab., 2015, 61, 1101-1108.
[55]
Kinde, I.; Munari, E.; Faraj, S.F.; Hruban, R.H.; Schoenberg, M.; Bivalacqua, T.; Allaf, M.; Springer, S.; Wang, Y.; Diaz, L.A.; Kinzler, K.W.; Vogelstein, B.; Papadopoulos, N.; Netto, G.J. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res., 2013, 73, 7162-7167.
[56]
Hosen, I.; Rachakonda, P.S.; Heidenreich, B.; De Verdier, P.J.; Ryk, C.; Steineck, G.; Hemminki, K.; Kumar, R. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int. J. Cancer, 2015, 137, 1621-1629.
[57]
Beukers, W.; Van Der Keur, K.A.; Kandimalla, R.; Vergouwe, Y.; Steyerberg, E.W.; Boormans, J.L.; Jensen, J.B.; Lorente, J.A.; Real, F.X.; Segersten, U.; Orntoft, T.F.; Malats, N.; Malmström, P.U.; Dyrskjot, L.; Zwarthoff, E.C. FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study. J. Urol., 2017, 197, 1410-1418.
[58]
Langfelder, P.; Horvath, S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics, 2008, 9, 559.
[59]
Giulietti, M.; Occhipinti, G.; Principato, G.; Piva, F. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis. Cell. Oncol., 2017, 40, 181-192.
[60]
Svetlovska, D.; Miskovska, V.; Cholujova, D.; Gronesova, P.; Cingelova, S.; Chovanec, M.; Sycova-Mila, Z.; Obertova, J.; Palacka, P.; Rajec, J.; Kalavska, K.; Usakova, V.; Luha, J.; Ondrus, D.; Spanik, S.; Mardiak, J.; Mego, M. Plasma cytokines correlated with disease characteristics, progression-free survival, and overall survival in testicular germ-cell tumor patients. Clin. Genitourin. Cancer, 2017, 15, 411-416.e2.
[61]
Syring, I.; Bartels, J.; Holdenrieder, S.; Kristiansen, G.; Müller, S.C.; Ellinger, J. Circulating Serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer. J. Urol., 2015, 193, 331-337.
[62]
Spiekermann, M.; Belge, G.; Winter, N.; Ikogho, R.; Balks, T.; Bullerdiek, J.; Dieckmann, K.P. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: Evaluations for establishing a serum biomarker. Andrology, 2015, 3, 78-84.
[63]
Dieckmann, K.P.; Spiekermann, M.; Balks, T.; Ikogho, R.; Anheuser, P.; Wosniok, W.; Loening, T.; Bullerdiek, J.; Belge, G. MicroRNA miR-371a-3p -A novel serum biomarker of testicular germ cell tumors: evidence for specificity from measurements in testicular vein blood and in neoplastic hydrocele fluid. Urol. Int., 2016, 97, 76-83.
[64]
IJzerman, M.J.; Berghuis, A.M.S.; De Bono, J.S.; Terstappen, L.W.M.M. Health economic impact of liquid biopsies in cancer management. Expert Rev. Pharmacoecon. Outcomes Res., 2018, 18(6), 593-599.
[65]
Tartari, F.; Santoni, M.; Burattini, L.; Mazzanti, P.; Onofri, A.; Berardi, R. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. Cancer Treat. Rev., 2016, 48, 20-24.
[66]
Di Meo, A.; Saleeb, R.; Wala, S.J.; Khella, H.W.; Ding, Q.; Zhai, H.; Krishan, K.; Krizova, A.; Gabril, M.; Evans, A.; Brimo, F.; Pasic, M.D.; Finelli, A.; Diamandis, E.P.; Yousef, G.M. A miRNA-based classification of renal cell carcinoma subtypes by PCR and in situ hybridization. Oncotarget, 2018, 9(2), 2092-2104.
[67]
Zhang, D.Z.; Lau, K.M.; Chan, E.S.; Wang, G.; Szeto, C.C.; Wong, K.; Choy, R.K.; Ng, C.F. Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. PLoS One, 2014, 9(7), e100793.
[68]
Daniel, R.; Wu, Q.; Williams, V.; Clark, G.; Guruli, G.; Zehner, Z. A Panel of microRNAs as diagnostic biomarkers for the identification of prostate cancer. Int. J. Mol. Sci., 2017, 18(6), 1281.
[69]
Tang, W.; Wan, S.; Yang, Z.; Teschendorff, A.E.; Zou, Q. Tumor origin detection with tissue-specific miRNA and DNA methylation markers. Bioinformatics, 2018, 34(3), 398-406.
[70]
Zeng, X.; Liu, L.; Lü, L.; Zou, Q. Prediction of potential disease-associated microRNAs using structural perturbation method. Bioinformatics, 2018, 34(14), 2425-2432.
[71]
Zeng, X.; Zhang, X.; Zou, Q. Integrative approaches for predicting microRNA function and prioritizing disease-related microRNA using biological interaction networks. Brief. Bioinform., 2016, 17(2), 193-203.
[72]
Ding, J.; Xing, Z.; Jiang, Z.; Chen, J.; Pan, L.; Qiu, J.; Xing, W. CT-based radiomic model predicts high grade of clear cell renal cell carcinoma. Eur. J. Radiol., 2018, 103, 51-56.
[73]
Tong, Y.; Udupa, J.K.; Wang, C.; Chen, J.; Venigalla, S.; Guzzo, T.J.; Mamtani, R.; Baumann, B.C.; Christodouleas, J.P.; Torigian, D.A. Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images. Adv. Radiat. Oncol., 2018, 3(3), 331-338.
[74]
Chaddad, A.; Niazi, T.; Probst, S.; Bladou, F.; Anidjar, M.; Bahoric, B. Predicting gleason score of prostate cancer patients using radiomic analysis. Front. Oncol., 2018, 8, 630.
[76]
Joice, G.A.; Rowe, S.P.; Gorin, M.A.; Pierorazio, P.M. Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases. Curr. Urol. Rep., 2018, 19(12), 110.
Download PDF Flyer